Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

A dual magnetic resonance imaging/fluorescent contrast agent for Cathepsin-D detection.

Ta R, Suchy M, Tam JH, Li AX, Martinez-Santiesteban FS, Scholl TJ, Hudson RH, Bartha R, Pasternak SH.

Contrast Media Mol Imaging. 2013 Mar-Apr;8(2):127-39. doi: 10.1002/cmmi.1502.

PMID:
23281285
2.

Prolonged In Vivo Retention of a Cathepsin D Targeted Optical Contrast Agent in a Mouse Model of Alzheimer's Disease.

Snir JA, Suchy M, Lawrence KS, Hudson RH, Pasternak SH, Bartha R.

J Alzheimers Dis. 2015;48(1):73-87. doi: 10.3233/JAD-150123.

PMID:
26401930
3.

Fast in vivo imaging of amyloid plaques using μ-MRI Gd-staining combined with ultrasound-induced blood-brain barrier opening.

Santin MD, Debeir T, Bridal SL, Rooney T, Dhenain M.

Neuroimage. 2013 Oct 1;79:288-94. doi: 10.1016/j.neuroimage.2013.04.106. Epub 2013 May 7.

PMID:
23660031
4.

Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice.

Kandimalla KK, Wengenack TM, Curran GL, Gilles EJ, Poduslo JF.

J Pharmacol Exp Ther. 2007 Aug;322(2):541-9. Epub 2007 May 15.

5.

Synthesis and characterization of a cell-permeable bimodal contrast agent targeting β-galactosidase.

Keliris A, Ziegler T, Mishra R, Pohmann R, Sauer MG, Ugurbil K, Engelmann J.

Bioorg Med Chem. 2011 Apr 15;19(8):2529-40. doi: 10.1016/j.bmc.2011.03.023. Epub 2011 Mar 13.

PMID:
21459584
6.

Detection of Aβ plaques by a novel specific MRI probe precursor CR-BSA-(Gd-DTPA)n in APP/PS1 transgenic mice.

Li S, He H, Cui W, Gu B, Li J, Qi Z, Zhou G, Liang CM, Feng XY.

Anat Rec (Hoboken). 2010 Dec;293(12):2136-43. doi: 10.1002/ar.21209.

7.
8.

Gadolinium-staining reveals amyloid plaques in the brain of Alzheimer's transgenic mice.

Petiet A, Santin M, Bertrand A, Wiggins CJ, Petit F, Houitte D, Hantraye P, Benavides J, Debeir T, Rooney T, Dhenain M.

Neurobiol Aging. 2012 Aug;33(8):1533-44. doi: 10.1016/j.neurobiolaging.2011.03.009. Epub 2011 Apr 30.

PMID:
21531045
9.

Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging.

Poduslo JF, Wengenack TM, Curran GL, Wisniewski T, Sigurdsson EM, Macura SI, Borowski BJ, Jack CR Jr.

Neurobiol Dis. 2002 Nov;11(2):315-29.

PMID:
12505424
10.

A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice.

Sigurdsson EM, Wadghiri YZ, Mosconi L, Blind JA, Knudsen E, Asuni A, Scholtzova H, Tsui WH, Li Y, Sadowski M, Turnbull DH, de Leon MJ, Wisniewski T.

Neurobiol Aging. 2008 Jun;29(6):836-47. Epub 2007 Feb 8.

11.

Selective contrast enhancement of individual Alzheimer's disease amyloid plaques using a polyamine and Gd-DOTA conjugated antibody fragment against fibrillar Abeta42 for magnetic resonance molecular imaging.

Ramakrishnan M, Wengenack TM, Kandimalla KK, Curran GL, Gilles EJ, Ramirez-Alvarado M, Lin J, Garwood M, Jack CR Jr, Poduslo JF.

Pharm Res. 2008 Aug;25(8):1861-72. doi: 10.1007/s11095-008-9600-9. Epub 2008 Apr 29.

12.

MR molecular imaging of prostate cancer with a peptide-targeted contrast agent in a mouse orthotopic prostate cancer model.

Tan M, Burden-Gulley SM, Li W, Wu X, Lindner D, Brady-Kalnay SM, Gulani V, Lu ZR.

Pharm Res. 2012 Apr;29(4):953-60. doi: 10.1007/s11095-011-0635-y. Epub 2011 Dec 3.

13.

In vivo magnetic resonance imaging of mice liver tumors using a new gadolinium-based contrast agent.

Chen SH, Kuo YT, Cheng TL, Chen CY, Chiu YY, Lai JJ, Chang CC, Jaw TS, Wang YM, Liu GC.

Kaohsiung J Med Sci. 2013 May;29(5):246-53. doi: 10.1016/j.kjms.2012.09.002. Epub 2013 Feb 13.

14.
15.

Synthesis and evaluation of a targeted nanoglobular dual-modal imaging agent for MR imaging and image-guided surgery of prostate cancer.

Tan M, Ye Z, Lindner D, Brady-Kalnay SM, Lu ZR.

Pharm Res. 2014 Jun;31(6):1469-76. doi: 10.1007/s11095-013-1008-5. Epub 2013 Mar 8.

16.

Detection of amyloid plaques targeted by USPIO-Aβ1-42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging.

Yang J, Wadghiri YZ, Hoang DM, Tsui W, Sun Y, Chung E, Li Y, Wang A, de Leon M, Wisniewski T.

Neuroimage. 2011 Apr 15;55(4):1600-9. doi: 10.1016/j.neuroimage.2011.01.023. Epub 2011 Jan 19.

17.

Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging.

Wadghiri YZ, Sigurdsson EM, Sadowski M, Elliott JI, Li Y, Scholtzova H, Tang CY, Aguinaldo G, Pappolla M, Duff K, Wisniewski T, Turnbull DH.

Magn Reson Med. 2003 Aug;50(2):293-302.

18.

6-Methyluracil derivatives as acetylcholinesterase inhibitors for treatment of Alzheimer's disease.

Zueva IV, Semenov VE, Mukhamedyarov MA, Lushchekina SV, Kharlamova AD, Petukhova EO, Mikhailov AS, Podyachev SN, Saifina LF, Petrov KA, Minnekhanova OA, Zobov VV, Nikolsky EE, Masson P, Reznik VS.

Int J Risk Saf Med. 2015;27 Suppl 1:S69-71. doi: 10.3233/JRS-150694.

PMID:
26639718
19.

Decreased expression of cathepsin D in monocytes is related to the defective degradation of amyloid-β in Alzheimer's disease.

Tian L, Zhang K, Tian ZY, Wang T, Shang DS, Li B, Liu DX, Fang WG, Wang ZY, Chen YH.

J Alzheimers Dis. 2014;42(2):511-20. doi: 10.3233/JAD-132192.

PMID:
24898658
20.

Detection of amyloid plaques targeted by bifunctional USPIO in Alzheimer's disease transgenic mice using magnetic resonance microimaging.

Wadghiri YZ, Li J, Wang J, Hoang DM, Sun Y, Xu H, Tsui W, Li Y, Boutajangout A, Wang A, de Leon M, Wisniewski T.

PLoS One. 2013;8(2):e57097. doi: 10.1371/journal.pone.0057097. Epub 2013 Feb 27.

Supplemental Content

Support Center